CSIMarket


Adial Pharmaceuticals Inc   (ADIL)
Other Ticker:  
 


 

Adial Pharmaceuticals Inc

ADIL's Financial Statements and Analysis



Adial Pharmaceuticals Inc increased third quarter of 2023 net loss per share of $-1.18 compare to net loss per share of $-0.12 recorded in the same quarter a year ago a decrease from $0.96 eps realized in II. Quarter (Jun 30 2023).


third quarter of 2023
Earnings Per Share Revenues
$ -1.18 $  0 Mill
$-1.06     Unch.    



Adial Pharmaceuticals Inc 's Revenue fell by 0 % in third quarter of 2023 (Sep 30 2023) year on year, to $0 million and declined by sequentially.


Adial Pharmaceuticals Inc is

More on ADIL's Income Statement



Adial Pharmaceuticals Inc in the third quarter of 2023 recorded net loss of $-1.385 million, an improvement compare to net loss of $-3.109 million in III. Quarter a year ago.

Sequentially company realized a net loss, compared to net income of $1.088 million in the previous quarter.

More on ADIL's Growth

Adial Pharmaceuticals Inc Inventories
In Sep 30 2023 company's net cash and cash equivalents decreased by $-1 million


Adial Pharmaceuticals Inc does not pay out common stock dividend.

In trailing twelve-month period Adial Pharmaceuticals Inc payed $ -6.22 cash per share, on a free-cash flow basis .

Book value fell by -32.30 % sequentially to $1.98 per share, -226.92% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 1.98 per share from $ 2.93.

Company issued 0.05 million shares or 4.16 % in Sep 30 2023.


More on ADIL's Dividends

 Market Capitalization (Millions) 1
 Shares Outstanding (Millions) 1
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -6
 Cash Flow (TTM) (Millions $) -5
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Adial Pharmaceuticals Inc does not pay out common stock dividend.

In trailing twelve-month period Adial Pharmaceuticals Inc had negative $ -6.22 cash flow per share, on a free-cash flow basis .

Book value fell by -32.30 % sequentially to $1.98 per share, -226.92% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 1.98 per share from $ 2.93.

Company issued 0.05 million shares or 4.16 % in Sep 30 2023.


More on ADIL's Balance Sheets

 Market Capitalization (Millions) 1
 Shares Outstanding (Millions) 1
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -6
 Cash Flow (TTM) (Millions $) -5
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Adial Pharmaceuticals Inc Earnings

ADIL Surprises Shareholders with Impressive Financial Turnaround in Q3 2023

The stock market has been buzzing with excitement as companies in various industries release their earnings reports for the third quarter of 2023. One industry that has garnered attention is Major Pharmaceutical Preparations, with several companies reporting their financial results. Among them, ADIL, a prominent player in the industry, has recently published its operating deficit for the quarter, and the numbers look promising.
ADIL announced an operating deficit of $-1.357936 million, indicating a significant improvement from the same reporting season last year, where the deficit stood at $-3.187693 million. This revelation is undoubtedly a positive sign for the company and has caught the attention of m...

Adial Pharmaceuticals Inc: Overcoming Challenges and Paving the Way for Innovation



Adial Pharmaceuticals Inc, a major player in the Major Pharmaceutical Preparations industry, recently released its financial results for the second quarter of 2023. While the company faced an operating shortfall, there are noteworthy aspects that indicate positive developments. This article aims to interpret these financial results and analyze their potential impact on the company's future prospects.
Operating Shortfall in Q2 2023:
Adial Pharmaceuticals Inc announced an operating shortfall of $-1.477395 million for the second quarter of 2023. However, the company's performance in day-to-day operations during this period has shown improvement compared to the same quarter the previous year. ...

Adial Pharmaceuticals Inc Reports Disappointing $13 Million Operating Loss in Q1 2023, Leading to Negative ROI

Adial Pharmaceuticals Inc Records $-13 Million Loss in Q1 2023 Resulting in Negative ROI, But Progress Made on Overall Ranking
In its recent financial report, Adial Pharmaceuticals Inc reported a cumulative net loss of $-13 million in the first quarter of 2023. This has resulted in negative return on investment (ROI) of -236.64%. While this news was disappointing for investors, it is important to note that the healthcare sector had 623 other companies with higher ROI.
However, on a positive note, the overall ROI ranking has progressed to 3184 in the Mar 31, 2023 quarter from the total ROI ranking of 4613 in the fourth quart...


Date modified: 2023-11-16T15:45:55+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com